BCMab1, a monoclonal antibody against aberrantly glycosylated Integrin α3β1, has potent antitumor activity of bladder cancer in vivo

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 4001-4013

  Li, Chong ^a   Yang, Zhao ^a   Du, Ying ^a   Tang, Haidong ^a   Chen, Jun ^a   Hu, Deqing ^a   Fan, Zusen ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCMAB 1 ANTIBODY; BIOLOGICAL MARKER; EPITOPE; MONOCLONAL ANTIBODY; N ACETYLGALACTOSAMINYLTRANSFERASE; RICIN A BCMAB 1 ANTIBODY; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 3; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL PHAGOCYTOSIS; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME GLYCOSYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; BAGG ALBINO MOUSE; CANCER GRADING; CANCER STAGING; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHAGOCYTOSIS; TUMOR CELL CULTURE; TUMOR INVASION; URINARY BLADDER NEOPLASMS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHA3BETA1; MICE; MICE, INBRED BALB C; MICE, NUDE; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHAGOCYTOSIS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905441209     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3397     Document Type: Article

References (40)

1. Gingrich JR. Bladder cancer: chemohyperthermia for bladder cancer-clinically effective? Nat Rev Urol 2011;8:414-6.
2. Soloway MS. Bladder cancer: lack of progress in bladder cancer-what are the obstacles? Nat Rev Urol 2013;10:5-6.
3. Gallagher DJ, Milowsky MI. Bladder cancer. Curr Treat Options Oncol 2009;10:205-15.
4. De Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, et al. Bladder cancer. Crit Rev Oncol Hematol 2002;41:89-106.
5. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-49.
6. Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 2000;7:325-34.
7. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
8. Kreidberg JA. Functions of alpha3beta1 integrin. Curr Opin Cell Biol 2000;12:548-53.
9. Kreidberg JA, Donovan MJ, Goldstein SL, Rennke H, Shepherd K, Jones RC, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996;122:3537-47.
10. Kremser ME, Przybylo M, Hoja-Lukowicz D, Pochec E, Amoresano A, Carpentieri A, et al. Characterisation of alpha3beta1 and alpha (v) beta3 integrin N-oligosaccharides in metastatic melanoma WM9 and WM239 cell lines. Biochim Biophys Acta 2008;1780:1421-31.
11. Litynska A, Przybylo M, Ksiazek D, Laidler P. Differences of alpha3-beta1 integrin glycans from different human bladder cell lines. Acta Biochim Pol 2000;47:427-34.
12. Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, et al. Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A 2010;107:10056-61.
13. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, et al. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res 2010;70:2759-69.
14. Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, et al. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest 2010;120:223-41.
15. Li C, Yan R, Bao J, Yuan G, Feng Y, Wang J, et al. Characterization of a novel transplantable orthotopic murine xenograft model of a human bladder transitional cell tumor (BIU-87). Cancer Biol Ther 2006;5:394-8.
16. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011;19:101-13.
17. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
18. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009;15:6008-17.
19. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009;4:251-85.
20. Wolfenson H, Lavelin I, Geiger B. Dynamic regulation of the structure and functions of integrin adhesions. Dev Cell 2013;24:447-58.
21. Kim C, Schmidt T, Cho EG, Ye F, Ulmer TS, Ginsberg MH. Basicaminoacid side chains regulate transmembrane integrin signalling. Nature 2012;481:209-13.
22. Jean C, Gravelle P, Fournie JJ, Laurent G. Influence of stress on extracellular matrix and integrin biology. Oncogene 2011;30:2697-706.
23. Morello V, Cabodi S, Sigismund S, Camacho-Leal MP, Repetto D, Volante M, et al. beta1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 2011;30:4087-96.
24. Ghosh S, Johnson JJ, Sen R, Mukhopadhyay S, Liu Y, Zhang F, et al. Functional relevance of urinary-type plasminogen activator receptoralpha3beta1 integrin association in proteinase regulatory pathways. J Biol Chem 2006;281:13021-9.
25. Pochec E, Litynska A, Bubka M, Amoresano A, Casbarra A. Characterization of the oligosaccharide component of alpha3beta1 integrin from human bladder carcinoma cell line T24 and its role in adhesion and migration. Eur J Cell Biol 2006;85:47-57.
26. Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S. A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9. J Biol Chem 2005;280:35545-53.
27. Laidler P, Gil D, Pituch-Noworolska A, Ciolczyk D, Ksiazek D, Przybylo M, et al. Expression of beta1-integrins and N-cadherin in bladder cancer and melanoma cell lines. Acta Biochim Pol 2000;47:1159-70.
28. Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, et al. Inactivating germ-line and somatic mutations in polypeptide N- acetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci U S A 2009;106:12921-5.
29. Kahai S, Lee SC, Lee DY, Yang J, Li M, Wang CH, et al. MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS ONE 2009;4:e7535.
30. Miwa HE, Gerken TA, Jamison O, Tabak LA. Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N- acetylgalactosaminyltransferase-1. J Biol Chem 2010;285:1208-19.
31. Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 2006;314:304-8.
32. Paszkiewicz-Gadek A, Porowska H, Lemancewicz D, Wolczynski S, Gindzienski A. The influence of N- and O-glycosylation inhibitors on the glycosylation profile of cellular membrane proteins and adhesive properties of carcinoma cell lines. Int J Mol Med 2006;17:669-74.
33. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009;119:252-66.
34. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A 2007;104:20302-7.
35. Bianchi-Smiraglia A, Paesante S, Bakin AV. Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 2013;32:3049-58.
36. Brunton VG, Avizienyte E, Fincham VJ, Serrels B, Metcalf CA, Sawyer TK, et al. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res 2005;65:1335-42.
37. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, et al. An integrin alpha (v) beta (3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009;15:1163-9.
38. Kostic A, Sheetz MP. Fibronectin rigidity response through Fyn and p130Cas recruitment to the leading edge. Mol Biol Cell 2006;17:2684-95.
39. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005;115:978-85.
40. Zhang FI, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011;29:149-53.